Dr. Bertrand Routy is an Assistant Professor of Hemato-Oncology and the Scientific Director of the Immunotherapy and Microbiome laboratory at the University of Montreal Research Center (CR-CHUM).
Dr. Routy received his MD from the University of Montreal and went on to graduate from McGill University’s Internal Medicine program. He completed a fellowship at the Princess Margaret Hospital, University of Toronto. Following his medical training, he obtained a PhD in immuno-oncology at the Gustave Roussy Cancer Campus in Paris under the supervision of Pr. Laurence Zitvogel.
Dr. Routy’s past work includes unraveling the harmful impact of antibiotics on patients receiving immune checkpoint blockers (ICB). He also contributed to establishing research revealing that the gut microbiota composition has a major impact on ICB efficacy in non-small cell lung cancer and renal cell carcinoma. He has written and published several seminal papers in journals including Science, Immunity, Cell and Annals of Oncology.
Dr. Routy’s research focuses on manipulation of the gut microbiome in combination with immunotherapy to develop novel therapies and biomarkers in thoracic oncology.